HealthMore in Health→
Biogen and Denali Pull Back a Parkinson’s Program After a Mid-Stage Failure
Key Takeaways
- Biogen and Denali’s LRRK2 inhibitor failed a Phase 2b study in early Parkinson’s disease.
- The companies are dropping the program in certain patients with non-genetic Parkinson’s.
- The supplied source text does not provide detailed study data, but it clearly establishes a strategic pullback.
DE
DT Editorial Team··via endpoints.news